Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials

Chimeric Antigen Receptor T-cell (CAR-T) therapy uses genetically engineered T-cells with specific binding sites. This therapy allows for tumor specificity and durable treatment responses for patients with hematological malignancies. In this review, we study the risk of venous thromboembolism (VTE)...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Akshit Chitkara, Sushanth Sreenivasan, Yue Yin, Maitreyee Rai, Santhosh Sadashiv
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2024-07-01
Serija:	Current Oncology
Teme:	Chimeric Antigen Receptor T-cell (CAR-T) venous thromboembolism meta-analysis hematological malignancies mantle cell lymphoma B-cell lymphoma
Online dostop:	https://www.mdpi.com/1718-7729/31/8/323
Oznake:	Označite Brez oznak, prvi označite!